Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: Implications for nanomedicine

Theranostics

Volumn 7, Issue 2, 2017, Pages 270-284

  Monguió Tortajada, Marta ^a   Roura, Santiago ^a,b   Gálvez Montón, Carolina ^a   Pujal, Josep Maria ^c   Aran, Gemma ^a   Sanjurjo, Lucía ^a   Franquesa, Marcella ^a,d   Sarrias, Maria Rosa ^a   Bayes Genis, Antoni ^a,d,e   Borràs, Francesc E ^a,d  

^a Germans Trias i Pujol Research Institute in Health Sciences   (Spain)

^b CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Exosomes; Immunomodulation; Inflammation; Nanosized extracellular vesicles; Size exclusion chromatography; Umbilical cord mesenchymal stem cell

Indexed keywords

5' NUCLEOTIDASE; CD63 ANTIGEN; CD9 ANTIGEN; THY 1 ANTIGEN; CONDITIONED MEDIUM; CYTOKINE; IMMUNOLOGIC FACTOR;

APOPTOSIS; ARTICLE; CELL POLARITY; CONDITIONED MEDIUM; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MONOCYTE; NANOMEDICINE; POLARIZATION; REGENERATIVE MEDICINE; SIZE EXCLUSION CHROMATOGRAPHY; T LYMPHOCYTE; TH17 CELL; ULTRACENTRIFUGATION; ULTRAFILTRATION; UMBILICAL CORD BLOOD CELL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES; SECRETION (PROCESS); ULTRASTRUCTURE; UMBILICAL CORD;

CELL PROLIFERATION; CRYOELECTRON MICROSCOPY; CULTURE MEDIA, CONDITIONED; CYTOKINES; EXTRACELLULAR VESICLES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MESENCHYMAL STROMAL CELLS; NANOMEDICINE; T-LYMPHOCYTES; UMBILICAL CORD;

EID: 85008450613     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.16154     Document Type: Article

References (70)

1. Roura S, Soler-Botija C, Bagó JR, et al. Postinfarction Functional Recovery Driven by a Three-Dimensional Engineered Fibrin Patch Composed of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. Stem Cells Transl. Med. 2015; 4:956-66.
2. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
3. Watt SM, Gullo F, van der Garde M, et al. The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Br. Med. Bull. 2013; 108:25-53.
4. Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26:591-9.
5. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-7.
6. Menard C, Pacelli L, Bassi G, et al. Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. Stem Cells Dev. 2013; 22:1789-1801.
7. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24:386-398.
8. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 2008; 38:1745-1755.
9. Renner P, Eggenhofer E, Rosenauer A, et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant. Proc. 2009; 41:2607-2611.
10. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007; 149:353-363.
11. de Witte SFH, Franquesa M, Baan CC, Hoogduijn MJ. Toward Development of iMesenchymal Stem Cells for Immunomodulatory Therapy. Front. Immunol. 2015; 6:648.
12. Regateiro FS, Howie D, Nolan KF, et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur. J. Immunol. 2011; 41:2955-2965.
13. Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J. Transl. Med. 2014; 12:260.
14. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619-4621.
15. Chen K, Wang D, Du WT, et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin. Immunol. 2010; 135:448-58.
16. Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013; 22:845-854.
17. Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials-an ISEV position paper. J. Extracell. vesicles 2015; 4:30087.
18. Yáñez-Mó M, Siljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. vesicles 2015; 4:27066.
19. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc. 2011; 26:1474-1483.
20. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010; 4:214-222.
21. Kordelas L, Rebmann V, Ludwig AK, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014; 28:970-3.
22. Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics 2013; 13:1637-1653.
23. Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 2014; 3.
24. Franquesa M, Hoogduijn MJ, Ripoll E, et al. Update on Controls for Isolation and Quantification Methodology of Extracellular Vesicles Derived from Adipose Tissue Mesenchymal Stem Cells. Front. Immunol. 2014; 5.
25. Fais S, O'Driscoll L, Borras FE, et al. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano 2016;
26. Conforti A, Scarsella M, Starc N, et al. Microvescicles Derived from Mesenchymal Stromal Cells Are Not as Effective as Their Cellular Counterpart in the Ability to Modulate Immune Responses In Vitro. Stem Cells Dev. 2014;
27. Gouveia de Andrade AV, Bertolino G, Riewaldt J, et al. Extracellular vesicles secreted by bone marrow-and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 2015; 24:1374-6.
28. Kim H-S, Choi D-Y, Yun SJ, et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J. Proteome Res. 2012; 11:839-49.
29. Murray PJJ, Allen JEE, Biswas SKK, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity 2014; 41:14-20.
30. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13.
31. Kilpinen L, Impola U, Sankkila L, et al. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. J. Extracell. Vesicles. 2013; 2.
32. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-. J. Immunol. 2010; 184:5885-5894.
33. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 2012; 12:383-396.
34. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin. Exp. Immunol. 2013; 171:1-7.
35. Mancheño-Corvo P, Menta R, del Río B, et al. T Lymphocyte Prestimulation Impairs in a Time-Dependent Manner the Capacity of Adipose Mesenchymal Stem Cells to Inhibit Proliferation: Role of Interferon?, P oly I:C, a nd Tryptophan Metabolism in Restoring Adipose Mesenchymal Stem Cell Inhibitory Effect. Stem Cells Dev. 2015; 24:2158-2170.
36. Groh ME, Maitra B, Szekely E, Koç ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 2005; 33:928-34.
37. Melief SM, Schrama E, Brugman MH, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013; 31:1980-1991.
38. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol. Cell Biol. 2010; 88:795-806.
39. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107:4817-24.
40. Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell. Immunol. 2011; 272:33-8.
41. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009; 18:683-92.
42. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5:54-63.
43. Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev. 2013; 22:2825-2835.
44. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen. Med. 2011; 6:481-492.
45. Zhao Y, Sun X, Cao W, et al. Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Acute Myocardial Ischemic Injury. Stem Cells Int. 2015; 2015:761643.
46. Yang J, Liu X-X, Fan H, et al. Extracellular Vesicles Derived from Bone Marrow Mesenchymal Stem Cells Protect against Experimental Colitis via Attenuating Colon Inflammation, Oxidative Stress and Apoptosis. PLoS One 2015; 10:e0140551.
47. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int. J. Mol. Sci. 2014; 15:4142-57
48. Baranyai T, Herczeg K, Onódi Z, et al. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. PLoS One 2015; 10:e0145686.
49. Gámez-Valero A, Monguió-Tortajada M, Carreras-Planella L, Franquesa M la, Beyer K, Borràs FE. Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents. Sci. Rep. 2016; 6:33641.
50. Yang Y, Bucan V, Baehre H, von der Ohe J, Otte A, Hass R. Acquisition of new tumor cell properties by MSC-derived exosomes. Int. J. Oncol. 2015; 47:244-52.
51. Amarnath S, Foley JE, Farthing DE, et al. Bone Marrow Derived Mesenchymal Stromal Cells Harness Purinergenic Signaling to Tolerize Human Th1 Cells In Vivo. Stem Cells 2014; 33:1-18.
52. Böing AN, van der Pol E, Grootemaat AE, Coumans FAW, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J. Extracell. vesicles 2014; 3.
53. de Menezes-Neto A, Sáez MJF, Lozano-Ramos I, et al. Size-exclusion chromatography as a stand-alone methodology identifies novel markers in mass spectrometry analyses of plasma-derived vesicles from healthy individuals. J. Extracell. vesicles 2015; 4:27378.
54. Lozano-Ramos I, Bancu I, Oliveira-Tercero A, et al. Size-exclusion chromatography-based enrichment of extracellular vesicles from urine samples. J. Extracell. vesicles 2015; 4:27369.
55. Welton JL, Webber JP, Botos L-A, Jones M, Clayton A. Ready-made chromatography columns for extracellular vesicle isolation from plasma. J. Extracell. vesicles 2015; 4:27269.
56. Plumas J, Chaperot L, Richard M-J, Molens J-P, Bensa J-C, Favrot M-C. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19:1597-604.
57. Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10:544-55.
58. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 2008; 9:650-7.
59. Benwell RK, Lee DR. Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin. Immunol. 2010; 134:178-87.
60. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int. Immunol. 2008; 20:1361-8.
61. Anderson JD, Johansson HJ, Graham CS, et al. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via NFkB Signaling. Stem Cells 2016; 34:601-13.
62. Rossi J-F, Lu Z-Y, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin. Cancer Res. 2015; 21:1248-57.
63. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124:188-95.
64. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014; 20:119-22.
65. Cutler AJ, Limbani V, Girdlestone J, Navarrete C V. Umbilical Cord-Derived Mesenchymal Stromal Cells Modulate Monocyte Function to Suppress T Cell Proliferation. J. Immunol. 2010; 185:6617-6623.
66. Melief SM, Geutskens SB, Fibbe WWE, et al. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 2013; 98:888-95.
67. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006; 177:7303-11.
68. Bayes-Genis A, Roura S, Soler-Botija C, et al. Identification of cardiomyogenic lineage markers in untreated human bone marrow-derived mesenchymal stem cells. Transplant. Proc. 2005; 37:4077-9.
69. Prat-Vidal C, Roura S, Farré J, et al. Umbilical cord blood-derived stem cells spontaneously express cardiomyogenic traits. Transplant. Proc. 2007; 39:2434-7.
70. Ullah M, Eucker J, Sittinger M, Ringe J. Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum. Stem Cell Res. Ther. 2013; 4:99.